Aduro Biotech, Inc. is a global immuno-oncology company that is developing treatments based on three broad, proprietary immunotherapy platforms that include STING pathway activators, B-select monoclonal antibodies and personalized LADD (live, attenuated double-deleted Listeria monocytogenes). Aduro’s immunotherapies are designed to potentially enhance efficacy by inducing highly targeted, potent and sustained innate and adaptive immune responses against a variety of cancers. Aduro Biotech is headquartered in Berkeley, California. Aduro Biotech Europe is a subsidiary based in Oss, Netherlands.